Estimated susceptibility of Canadian meningococcal B isolates to a meningococcal serogroup B vaccine (MenB-FHbp). Issue 8 (18th February 2020)

• Record Type: Journal Article
• Authors: Bettinger, Julie A.; Liberator, Paul; Halperin, Scott A.; Vaudry, Wendy; Sadarangani, Manish; Hao, Li; Lambert, Nathaniel; Jansen, Kathrin U.; Anderson, Annaliesa S.; Tsang, Raymond
• Is Part Of: Vaccine. Volume 38:Issue 8(2020)
• Page Start: 2026
• Page End: 2033
• Publication Date: 2020-02-18
• Subjects: Factor H binding protein -- Invasive meningococcal disease -- Neisseria meningitidis; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2019.12.051
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: 91.2% of Canadian MenB isolates tested expressed fHbp at levels predicted to be susceptible to the MenB-FHbp vaccine. Peptide 15 (B44, 1.15) was most prevalent and had the highest levels of fHbp surface expression. fHbp variant type and expression varied by age and region. Abstract: Background: Invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) remains a health risk in Canada and globally. Two MenB vaccines are now approved for use. An understanding of the genotype of Canadian strains and the potential strain coverage conferred by the MenB-FHbp vaccine is needed to inform immunization policies. Methods: Serogroup B Neisseria meningitidis strains responsible for meningococcal disease in Canada from 2006 to 2012 were collected as part of the Canadian Immunization Monitoring Program Active surveillance network. Genotypic analysis was done on MenB isolates from 2006 to 2012 with determination of fHbp surface expression for a subset of isolates: those occurring from 2010 to 2012. Results: Two clonal complexes (cc269 and cc41/44) were observed in 68.8% of the 276 isolates. A total of 50 different fHbp peptides were identified among isolates from 2006 to 2012. Surface expression of fHbp was detected on 95% of MenB isolates from 2010 to 2012 and 91% of isolates expressed fHbp at levels that are predicted to be susceptible to the bactericidal immune response elicited by the MenB-FHbp vaccine. Some regional differences were observed, particularly in isolates from British Columbia and Quebec. Conclusion: The majority of MenB isolates responsible for meningococcal disease in Canada expressed fHbp at levels predicted to be sufficient for complement mediated bactericidal activity in the presence of MenB-FHbp induced serum antibodies.